Molbio Diagnostics shares jumped after Jefferies initiated coverage with a Buy rating and named it a high-conviction top pick. The brokerage set a Rs 1,600 target price, implying 27% upside from Tuesday’s close and nearly 98% above its Rs 807 IPO price. The stock had listed at a 21% premium at Rs 980.